Aditxt Past Earnings Performance
Past criteria checks 0/6
Aditxt's earnings have been declining at an average annual rate of -30.3%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 48.7% per year.
Key information
-30.3%
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 48.7% |
| Return on equity | -909.2% |
| Net Margin | -19,217.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Aditxt gains on regaining compliance with Nasdaq listing requirements
Sep 29Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split
Sep 13Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate
Jul 08Aditxt adds Lauren Chung to board of directors
Jun 18Aditxt, Todos Medical in distribution pact for for COVID-19 immune monitoring
Dec 14We Think ADiTx Therapeutics (NASDAQ:ADTX) Can Afford To Drive Business Growth
Nov 23
Revenue & Expenses Breakdown
How Aditxt makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -41 | 15 | 14 |
| 30 Jun 24 | 0 | -43 | 19 | 15 |
| 31 Mar 24 | 1 | -41 | 18 | 14 |
| 31 Dec 23 | 1 | -33 | 19 | 7 |
| 30 Sep 23 | 1 | -30 | 20 | 6 |
| 30 Jun 23 | 1 | -27 | 17 | 7 |
| 31 Mar 23 | 1 | -28 | 18 | 7 |
| 31 Dec 22 | 1 | -28 | 18 | 7 |
| 30 Sep 22 | 1 | -43 | 21 | 6 |
| 30 Jun 22 | 1 | -46 | 22 | 6 |
| 31 Mar 22 | 0 | -46 | 22 | 6 |
| 31 Dec 21 | 0 | -46 | 22 | 5 |
| 30 Sep 21 | 0 | -27 | 19 | 4 |
| 30 Jun 21 | 0 | -20 | 17 | 3 |
| 31 Mar 21 | 0 | -14 | 12 | 2 |
| 31 Dec 20 | 0 | -9 | 8 | 1 |
| 30 Sep 20 | 0 | -5 | 5 | 1 |
| 30 Jun 20 | 0 | -4 | 3 | 0 |
| 31 Mar 20 | 0 | -6 | 5 | 0 |
| 31 Dec 19 | 0 | -6 | 6 | 0 |
| 30 Sep 19 | 0 | -5 | 5 | 0 |
| 30 Jun 19 | 0 | -6 | 5 | 0 |
| 31 Mar 19 | 0 | -5 | 4 | 1 |
| 31 Dec 18 | 0 | -6 | 5 | 1 |
Quality Earnings: ADTX is currently unprofitable.
Growing Profit Margin: ADTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ADTX is unprofitable, and losses have increased over the past 5 years at a rate of 30.3% per year.
Accelerating Growth: Unable to compare ADTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ADTX has a negative Return on Equity (-909.19%), as it is currently unprofitable.